Cartesian Therapeutics to Participate in Upcoming Investor Conferences
GAITHERSBURG, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in March:
- A presentation at the 2024 Leerink Partners Global Biopharma Conference at 8:40 a.m. ET on Wednesday, March 13, 2024 in Miami, FL
- A fireside chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference at 11:00 a.m. ET on Tuesday, March 26, 2024
A live webcast of the presentation and fireside chat are expected to be accessible in the Events section of the Company’s website at , where an archived replay of the events will also be available for a limited time.
About Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a potential first-in-class mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis. Additional Phase 2 studies are planned in systemic lupus erythematosus under an allowed IND, as well as basket trials in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T. Cartesian operates a wholly owned, state-of-the-art cGMP manufacturing facility in Gaithersburg, MD. Learn more at and follow us on and , formerly known as Twitter.
Contact Information:
Investor Relations:
Melissa Forst
Argot Partners
Media:
David Rosen
Argot Partners
